Dianthus Therapeutics, Inc. (DNTH) Earnings History
Net Loss10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Dianthus Therapeutics, Inc. (DNTH) Earnings Overview
As of July 7, 2026, Dianthus Therapeutics, Inc. (DNTH) reported trailing twelve-month net income of -$11M, reflecting -64.7% year-over-year growth. The company earned $-0.24 per diluted share over the past four quarters, with a net profit margin of -7973.3%.
Looking at the long-term picture, DNTH's historical earnings data spans multiple years. The company achieved its highest annual net income of -$9M in fiscal 2016.
Dianthus Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ALXO (-$89M net income), BCAB (-$51M net income, -2980.3% margin), IMVT (-$506M net income), DNTH has comparable earnings metrics. Compare DNTH vs ALXO →
DNTH Earnings vs Peers
Earnings metrics vs comparable public companies
DNTH Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$162M | -91.1% | -$178M | $-4.20 | -7973.3% | -8739.3% |
| 2024 | -$85M | -95.1% | -$102M | $-2.55 | -1362.8% | -1633.7% |
| 2023 | -$44M | -53.0% | -$48M | $-8.45 | -1541.2% | -1704.7% |
| 2022 | -$28M | -117.2% | -$30M | $-7.60 | -443.8% | -462.9% |
| 2021 | -$13M | +82.5% | -$13M | $-3.82 | -888.1% | -886.6% |
| 2020 | -$75M | +2.4% | -$79M | $-27.30 | - | - |
| 2019 | -$77M | -33.5% | -$83M | $-33.18 | - | - |
| 2018 | -$58M | -62.1% | -$60M | $-27.62 | - | - |
| 2017 | -$35M | -276.3% | -$36M | $-16.05 | - | - |
| 2016 | -$9M | - | -$9M | $-4.27 | - | - |
Download Data
Export DNTH earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DNTH — Frequently Asked Questions
Quick answers to the most common questions about buying DNTH stock.
What is DNTH earnings per share (EPS)?
DNTH trailing twelve-month (TTM) diluted EPS is $-0.24, reflecting -64.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Dianthus Therapeutics, Inc.'s net income?
Dianthus Therapeutics, Inc. (DNTH) trailing twelve-month net income is $-11M as of 2025. Earnings declined -64.7% year-over-year.
Is DNTH profitable?
DNTH is not currently profitable on a TTM basis, reporting a net loss of $-11M. Net margin is -7973.3%. Investors should monitor for a return to profitability.
What is DNTH's earnings growth rate?
DNTH compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are DNTH's profit margins?
Dianthus Therapeutics, Inc. net profit margin is -7973.3%, operating margin is -8739.3%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -38.4%.
Is DNTH growing earnings?
DNTH earnings are declining — EPS fell -64.7% year-over-year. TTM net income dropped to $-11M. This contrasts with the 5-year CAGR of N/A.
What was DNTH's best earnings year?
Dianthus Therapeutics, Inc.'s highest annual net income on record is $-9M, achieved in fiscal year 2016. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were DNTH's earnings last quarter?
DNTH's most recent reported quarter was Q1 2026. Net income was $-41M with diluted EPS of $-0.85. For a full breakdown of all quarters, see the quarterly earnings table on this page.